• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

shRNA

shRNA Platform

Short hairpin RNA (shRNA) technology offers a differentiated strategy to future development of CAR T-cell therapies

Manipulating protein expression to generate cells with a specific desired feature is one of the central goals of engineered cell therapy. Short hairpin RNA (shRNA) is a well-established approach to reduce protein expression by silencing genes in a process called RNA interference.

Celyad Oncology’s shRNA technology allows for the modulation of gene expression in our CAR constructs without the need for gene-editing. We are currently engineering T-cells with specific desired features, including the reduced alloreactivity, increased persistence and enhanced anti-tumor activity or potentially improved tolerability. We have validated the utility, versatility and safety of our shRNA platform through our clinical pipeline candidates. Our next-generation NKG2D-based CAR T-cell clinical candidate, CYAD-02, incorporates a single shRNA hairpin targeting the NKG2D ligands MICA/MICB within the construct, and our BCMA-targeting CAR T-cell candidate, CYAD-211, incorporates a single shRNA hairpin targeting the CD3ζ component of the TCR complex.

Innovative multiplexing technology goes beyond allogeneic CAR T-cell therapy

The shRNA technology was first validated by creating off-the-shelf allogeneic CAR T-cells where the expression of CD3ζ was modulated in the CYAD-211 product candidate.

The shRNA technology can be further adapted through multiplexing: shRNA multiplexing is a unique capability where multiple genes can be modulated simultaneously, whether cell source is of autologous or allogeneic origin.

fx1_lrg

Our shRNA platform provides a versatile approach to control gene expression and optimize function of T-cells.

Thereby multiplexing allows to:

  • Optimize CAR T-cell features, e.g. persistence, efficacy, or ability to evade complex or immunosuppressive tumor microenvironments, by modulating genes involved in alloreactivity, allorejection, fratricide, T-cell persistence and/or immunosuppression,
  • Provide potential for broad therapeutic functionality, which is especially important in the context of solid tumors,
  • Be complementary to our All-in-One Vector approach to express multiple shRNAs in a single construct within a single transduction step.
targets for multiplex
Read our recent publication about our microRNA (miRNA)-based multiplex shRNA platform technology

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use